TxCell Stock price

Equities

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time Euronext Paris 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Dynamic Chart
Managers TitleAgeSince
President 62 22-09-29
Public Communications Contact - 16-02-29
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Chairman - 19-02-11
More insiders
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
More about the company
  1. Stock
  2. Equities
  3. Stock TxCell - Euronext Paris